Bet bromodomain inhibition reverse hiv latency ex vivo

HIGHLIGHTS

• who: Combined noncanonical NF-u03baB agonism and colleagues from the UNC HIV Cure Center, University of of Pharmacy, Chapel Hill, North Carolina, USA have published the research: BET bromodomain inhibition reverse HIV latency ex vivo, in the Journal: (JOURNAL)
• what: This study was approved by the Biomedical Institutional Review Board of UNC, and all participants provided written, informed consent prior to participation.
• future: Consideration of the potential mechanisms of IAPi+BETi-mediated HIV transcription in aviremic donor CD4+ T_cells in the absence of high levels of Tat may provide useful insight into development . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.